The reliability of response to treatment is an important component of erectile dysfunction (ED) treatment. This study examined the reliability of tadalafil once daily (that is, successful attempts/total attempts) following initial successful intercourse. Data pooled from two randomized, double-blind, placebo-controlled trials of men with ED who received tadalafil 2.5 mg (N ¼ 96), tadalafil 5 mg (N ¼ 206) or placebo (N ¼ 148) once daily were analyzed to determine the first-attempt success rate and subsequent reliability of response. The first-attempt success rate (Sexual Encounter Profile question 3 (SEP3)) was significantly higher among men taking tadalafil 2.5 mg (45.7%) and 5 mg (55.2%) compared to placebo (28.5%; Po0.05 and Po0.001, respectively). Furthermore, following initial success, men taking tadalafil 5 mg had a significantly greater proportion of successful intercourse (SEP3) on subsequent attempts (85.9%, Po0.001) compared to men taking placebo (70.2%). Overall, men with ED taking tadalafil once daily experienced a high rate of reliability of efficacy.
Introduction
Erectile dysfunction (ED) is defined by the National Institutes of Health as 'the inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse'. 1 Estimates suggest that ED affects approximately 150 million men worldwide, and the rates of ED are expected to double by the year 2025. 2, 3 A number of therapeutic options are available to treat men with ED; of these, oral phosphodiesterase type 5 (PDE5) inhibitors are recommended as a first line of therapy. 4 An important factor in the management of ED is the reliability of the medication over time. 5, 6 Reliability refers to the consistent response to an ED medication, and has also been referred to as 'maintenance of success' in the literature. 5 Reliable erectile function is an important aspect of quality of life for men. 7 For men with ED, a lack of reliable erectile function can interfere greatly with psychosocial functioning and self-esteem. 8 The reliability of tadalafil when taken on an asneeded basis has been demonstrated. Schulman et al. 5 conducted an integrated analysis of five placebo-controlled studies of men with ED treated with tadalafil 10 mg (N ¼ 321), tadalafil 20 mg (N ¼ 258) or placebo N ¼ 308) for 12 weeks. They examined several factors including first-dose success as well as maintenance of success among men with first-dose success. The Sexual Encounter Profile (SEP) diary was used to assess success. Compared to placebo, a significantly greater proportion of men treated with tadalafil 10 and 20 mg reported successfully achieving an erection, successful penetration, successful intercourse and satisfaction with the overall sexual experience. For men with first-dose success, the success rate for subsequent attempts was significantly greater among those taking tadalafil 10 and 20 mg versus placebo. Specifically, in those patients with success on the first-dose attempt, successful completion of intercourse (that is, 'yes' to SEP3) was reported for 81% and 88% of subsequent attempts among men taking tadalafil 10 and 20 mg, respectively, compared to 64% of subsequent attempts among men taking placebo (Po0.001).
The efficacy and safety of tadalafil administered once daily has been established in three doubleblind, placebo-controlled clinical studies, two conducted in the general ED population 9, 10 and one in patients with ED and diabetes. 11 These studies demonstrated that tadalafil 2.5mg, 5mg and 10 mg administered once daily compared to placebo is a safe and effective treatment for ED. Daily treatment with tadalafil 2.5 and 5 mg was approved by the US Food and Drug Administration in January 2008 based on the safety and efficacy profile.
To date, no study has examined the reliability of efficacy (that is, number of successful attempts/total number of attempts) following initial success with tadalafil once daily treatment. The objective of this analysis was to evaluate the reliability of response in men treated with tadalafil 2.5 and 5 mg daily by assessing the rate of successful intercourse on subsequent attempts following successful intercourse.
Methods

Study design
Data were pooled from two randomized, doubleblind, placebo-controlled trials of men with ED. Both studies were reviewed and approved by the Ethics Review Boards at each participating site, and all patients provided written informed consent before undergoing any protocol procedure or receiving any protocol treatment. The patients in this analysis received tadalafil 2.5 mg (N ¼ 96), tadalafil 5 mg (N ¼ 206) or placebo (N ¼ 148). Eligibility and exclusion criteria were fully described in previous reports. 9, 10 In brief, men who were X18 years of age with at least a 3-month history of ED were eligible for the study. Patients were excluded if they had untreated endocrine disease, a history of radical prostatectomy or other pelvic surgery, hepatic insufficiency, unstable cardiovascular status, clinically significant penile deformities or penile implants. Men who did not respond, in the opinion of the investigator, to previous use of other PDE5 inhibitors were excluded from the study.
Assessments
The SEP diary has been used in multiple studies of ED treatment. It is an immediate recall instrument, which allows the patient to document each sexual attempt during the course of the study. The percentage of 'yes' responses to the following SEP questions were assessed in this analysis: SEP2 'Were you able to insert your penis into your partner's vagina?'; SEP3 'Did your erection last long enough for you to have successful intercourse?'; SEP4 'Were you satisfied with the hardness of your erection?' and SEP5 'Were you satisfied overall with this sexual experience?'.
Definition and measurement of reliability
An operational definition of reliability of efficacy was established. Reliability was defined as the rate of subsequent successful intercourse following a successful attempt. This was measured as the mean per-patient percentage of 'yes' responses to SEP3 for all subsequent attempts following a successful attempt.
Statistical methods
The established hierarchy for SEP analysis dictates that if a patient answers 'no' to a SEP question for an attempt, all subsequent SEP questions related to the same attempt are automatically assigned as 'no' regardless of how the patient answers in the diary. For example, if the response is 'no' to SEP1, then SEP2 through SEP5 are also coded as 'no'; if the response is 'yes' to SEP1 and SEP2 but 'no' to SEP3, then SEP4 and SEP5 are assigned as a 'no' response.
For the purposes of analysis, the reliability of treatment was defined and measured as the mean per-patient success rate on subsequent attempts following successful intercourse (that is, number of subsequent attempts with 'yes' response to SEP 3/total number of subsequent attempts with a valid diary entry). Patients who had successful attempts during the course of the study were categorized by whether they responded positively to SEP3-SEP5 at their first attempt (versus at a later attempt). The first-attempt success rate and satisfaction rate were calculated as the proportion of first attempts after the start of therapy with a 'yes' response to SEP2, SEP3, SEP4 and SEP5. Fisher's exact test was used for treatment comparisons. For patients who responded 'yes' to SEP4 and SEP5 at the first attempt, mean per-patient response rate for SEP4 and SEP5 on subsequent attempts during the 12 weeks was also assessed. Treatment comparisons were performed using the analysis of covariance (ANCOVA) model, and the model included treatment, study and baseline value of the variable.
Likewise, for those who did not respond 'yes' to SEP3, SEP4 or SEP5 at the first attempt, success rates were calculated following the first 'yes' response to each question on a subsequent attempt. Similar ANCOVA models were applied to compare the response rates for subsequent attempts between the treatment groups. Lastly, the cumulative percentage of patients who achieved intercourse success ('yes' to SEP3) by the number of sexual intercourse attempts was calculated.
Results
Patient characteristics
The mean age of patients studied was similar across treatment groups (Table 1) . The majority of patients Reliability of efficacy of tadalafil once daily R Shabsigh et al in all three groups were Caucasian. More than half of the patients had ED that was of organic etiology and the majority of patients had ED of at least 1-year duration. Patient demographic and baseline characteristics are fully described elsewhere.
8,9
First attempt The first-time sexual intercourse attempt success rate and satisfaction rates for the three treatment groups are presented in Figure 1 . Significantly greater successful penetration rates (SEP2) at the first attempt were reported for tadalafil 2.5 and 5 mg groups (Po0.05 and Po0.001, respectively) compared to the placebo group. Significantly greater successful intercourse rates (SEP3) at the first attempt were reported for tadalafil 2.5 and 5 mg (Po0.05 and Po0.001, respectively) compared with the placebo group. Satisfaction with the first attempt was also evaluated. Satisfaction with erection hardness (SEP4) was significantly greater only in the tadalafil 5 mg group (Po0.001) compared to placebo. Satisfaction with the overall sexual experience (SEP5) was significantly greater in both the tadalafil 2.5 and 5 mg groups (Po0.05 and Po0.001, respectively) compared to placebo. Among these patients who had successful intercourse on their first attempt, responses varied by baseline ED severity and age ( Figure 2 ). Baseline ED severity was determined by patients' baseline International Index of Erectile Function-Erectile 12-14 For men with mild or moderate ED at baseline (mild score equal to 17 or above; moderate score 11-16), significantly greater successful intercourse rates were reported for both tadalafil 2.5 and 5 mg (Po0.05 and Po0.001, respectively) compared to placebo. However, for men with severe ED at baseline (score of 10 or less), significantly greater successful intercourse rates were reported only for tadalafil 5 mg group (Po0.001) compared to the placebo group. Significantly greater successful intercourse rates (SEP3) were reported by men p65 years of age in both the tadalafil 2.5 and 5 mg groups (Po0.05 and Po0.001, respectively) compared to placebo, whereas for men aged 465 no significant differences emerged.
Subsequent attempts
Reliability, that is, success on subsequent intercourse attempts, among patients who reported firstattempt success is presented in Figure 3a . Achieving successful intercourse ('yes' to SEP3) was reported for a significantly greater proportion of subsequent attempts by men receiving tadalafil 5 mg (Po0.001) compared to men receiving placebo. Men treated with tadalafil 2.5 mg had a numerically higher rate of subsequent successful intercourse compared to placebo, but the difference did not reach statistical significance.
Additionally, satisfaction among men who responded 'yes' to SEP4 and/or SEP5 at the first attempt was assessed. Satisfaction with erection hardness (SEP4) was reported for a significantly greater proportion of subsequent intercourse attempts among men taking both tadalafil 2.5 and 5 mg (Po0.05 and Po0.001, respectively) compared to placebo. Also, the rate of overall satisfaction with the sexual experience (SEP5) was significantly higher for both the tadalafil 2.5 and 5 mg groups (Po0.05 and Po0.001, respectively) compared to the placebo group.
For those men who had successful intercourse at some point during the study but who were not successful with the first sexual attempt, the average number of intercourse attempts to become successful was determined. Men in the tadalafil 2.5 mg group made, on average, 4.5 attempts (range 2-24) to have successful intercourse ('yes' to SEP3), compared to 4.1 attempts (range 2-23) for men in the tadalafil 5 mg group and 5.3 attempts (range 2-29) for men in the placebo group.
Among those men who were not successful on the first attempt but were successful on subsequent attempts, their success for subsequent intercourse attempts during the treatment period is presented in Figure 3b . Men treated with both tadalafil 2.5 and 5 mg had a significantly higher rate of subsequent 
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R Shabsigh et al successful intercourse (SEP3; Po0.05 and Po0.001, respectively) compared to the placebo group. The rate of satisfaction with erection hardness (SEP4) was significantly greater for the tadalafil 5 mg group (Po0.05) compared to placebo; the rate for the tadalafil 2.5 mg group was higher than placebo, but this difference did not reach statistical significance.
Rates of overall satisfaction with the sexual experience (SEP5) were significantly higher in both the tadalafil 2.5 and 5 mg groups (Po0.05 and Po0.05, respectively) compared to placebo. Across groups, men who were successful on their first attempt had higher response rates on successful intercourse, satisfaction with erection hardness and overall satisfaction with the sexual experience, than men who were not successful on their first attempt (Table 2 ). For example, among men taking tadalafil 2.5 or 5 mg, those who had success on the first attempt had better reliability (SEP3) during treatment (74.4 and 85.9%, respectively) than those who did not have success on the first attempt (51.9 and 57.7%, respectively).
The demographic and baseline characteristics of men who had success on the first attempt varied somewhat from men who did not have first-attempt success (Table 3) . Across treatment groups, a higher percentage of men with a successful first attempt had mild ED and generally less comorbidities.
Reliability, that is, subsequent successful intercourse (SEP3), varied somewhat by severity of ED at baseline and age for men who had a successful first attempt (Figure 4a ) as well as men who did not (Figure 4b ). Among men who had success at the first attempt, men with mild and moderate ED at baseline who were treated with tadalafil 5 mg had a significantly better reliability rate (Po0.001) compared to placebo, whereas for men with severe ED at baseline, no significant differences emerged.
Significant differences by ED severity did not emerge in the tadalafil 2.5 mg group. Men in both the p65 and 465 years age groups who were treated with tadalafil 5 mg had significantly better reliability (Po0.05 and Po0.05, respectively) compared to placebo. Differences by age group for the 2.5 mg group were not significant.
Among men who did not have success at the first attempt, those treated with tadalafil 5 mg reported a significantly higher reliability rate (Po0.05) compared to placebo, regardless of ED severity at baseline. Significant differences did not emerge in the tadalafil 2.5 mg group by ED severity in men who did not have a successful first attempt. Men p65 years of age who were treated with tadalafil 2.5 and 5 mg had a significantly higher reliability rate (Po0.05) compared to placebo, but for men 465 years no significant differences emerged.
The cumulative proportion of men who achieved successful intercourse at any time during the study is presented in Figure 5 . For all three treatment groups, the cumulative proportion of men who achieved successful intercourse increased, reaching a plateau at approximately the tenth attempt.
Discussion
It is important that men are able to expect a reliable response from their ED medication. The results of this integrated analysis showed that tadalafil 2.5 and 5 mg taken on a once daily basis provided a reliable treatment response over 12 weeks. Men who were successful on the first intercourse attempt were able to maintain a subsequent level of success (SEP3) that was significantly greater for men taking tadalafil 5 mg once daily versus placebo. For men taking the 2.5 mg dose, the subsequent success rate (SEP3) was Abbreviations: N, number of patients who were randomized to each treatment; n, number of patients who had success with first attempt and had at least one subsequent attempt following initial success or number of patients who had success but not on the first attempt and had at least one subsequent attempt following the success in each treatment group; SEP, Sexual Encounter Profile. There were 144, 92 and 201 patients in placebo, tadalafil 2.5 and 5 mg groups, respectively, who had at least one valid SEP diary entry during the treatment.
Reliability of efficacy of tadalafil once daily R Shabsigh et al higher than placebo but the difference did not reach statistical significance. At the first sexual intercourse attempt, only men taking tadalafil 5 mg (versus 2.5 mg) once daily were significantly more likely to have achieved successful penetration, completion of intercourse, satisfaction with erection hardness and overall satisfaction with the sexual experience compared to men taking placebo. They also reported significantly greater rates of intercourse success and satisfaction on subsequent attempts.
It appears important to optimize early success; this analysis suggests it may lead to better reliability and greater satisfaction. Men taking tadalafil 5 mg who were successful on the first attempt had higher reliability, with success rates of at least 80% compared to those who did not have first-attempt success. Likewise, satisfaction was higher among There were 144, 92 and 201 patients in placebo, tadalafil 2.5 and 5 mg groups, respectively, who had at least one valid SEP diary entry during the treatment. Success at first attempt was determined by SEP3 response. Patients who had no success during the treatment period (based on the response to SEP3) were excluded.
Reliability of efficacy of tadalafil once daily R Shabsigh et al those men who were successful with their first attempt versus those who were not. The percentage of men who reported successful intercourse increased over time. Among the men in this sample, regardless of success on the first attempt, intercourse success rates increased reaching a plateau of approximately 75-80%. Men who are not initially successful may become discouraged and discontinue therapy. Therefore it is important to encourage men who may not be initially successful to continue therapy.
There are no head-to-head studies comparing the reliability of daily tadalafil to tadalafil as needed; however, one could historically compare the findings of this analysis to the reliability of tadalafil taken as needed as reported by Schulman et al. 5 The reliability for subsequent attempts for patients treated with tadalafil 5 mg once daily (86%) was comparable to that reported by patients taking tadalafil 20 mg as needed (88%). 5 Although a rate of 70.2% of subsequent success among men taking placebo who had a successful first attempt may seem high, it should be noted that less than one-third (28.5%) of placebo-treated men were successful with their first sexual intercourse attempt. The rate of subsequent success for these men may be attributable to the fact that most had mild ED at baseline. Men taking placebo who did not have a first successful intercourse attempt had a subsequent successful intercourse rate of just 37.3%.
A few limitations to this analysis should be noted. First, IIEF-EF scores identified that more than half of the patients had mild and moderate ED at baseline. Also, this retrospective analysis included pooled data from two studies in which the number of patients who qualified for the various subgroups was limited. Future studies should include a greater number of men and those with more severe ED.
Conclusions
The reliability of efficacy for tadalafil taken once daily was demonstrated in this analysis. Overall, men with ED taking either tadalafil 2.5 or 5 mg once daily experienced a high rate of reliability compared to placebo. Overall, the men taking tadalafil 5 mg and who were initially successful experienced the best results. This information may be useful to practitioners when discussing ED treatment expectations with their patients. Finally, as expected, younger men and those with milder ED had better rates of reliability as well as greater satisfaction. Reliability, that is, a consistent response to treatment, should be an important factor for the physician and patient to discuss in choosing an ED treatment. Reliability of efficacy of tadalafil once daily R Shabsigh et al
